These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 9872009)
1. [Importance of recombinant proteins in the adjuvant treatment of cancer]. Cheron JM Ann Pharm Fr; 1998; 56(6):241-3. PubMed ID: 9872009 [TBL] [Abstract][Full Text] [Related]
2. Current role of chemotherapy protectors in cancer treatment. Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052 [TBL] [Abstract][Full Text] [Related]
3. Current and future use of hematopoietic growth factors in cancer medicine. Mughal TI Hematol Oncol; 2004 Sep; 22(3):121-34. PubMed ID: 15991222 [TBL] [Abstract][Full Text] [Related]
4. Prophylactic use of myelopoietic growth factors in children after myelosuppressive and myeloablative therapy. Satwani P; Bessmertny O; Morris E; Cairo MS Curr Hematol Rep; 2003 Nov; 2(6):480-90. PubMed ID: 14561392 [TBL] [Abstract][Full Text] [Related]
5. Hematopoietic growth factors in cancer chemotherapy. Crawford J; Foote M; Morstyn G Cancer Chemother Biol Response Modif; 1999; 18():250-67. PubMed ID: 10800487 [TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of myeloid growth factors in cancer chemotherapy. Lyman GH; Kuderer NM Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer. Gunawardana DH; Basser RL; Davis ID; Cebon J; Mitchell P; Underhill C; Kilpatrick TJ; Reardon K; Green MD; Bardy P; Amor P; Crump D; Ng S; Nation RL; Begley CG Clin Cancer Res; 2003 Jun; 9(6):2056-65. PubMed ID: 12796368 [TBL] [Abstract][Full Text] [Related]
14. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use]. Paul C; Hast R Lakartidningen; 2000 Jun; 97(23):2862-6. PubMed ID: 10885223 [No Abstract] [Full Text] [Related]
15. Hematopoietic growth factors. A promising future for use in bone marrow dysfunction. Mazza JJ; Reding DJ; Plank GS Postgrad Med; 1992 Jun; 91(8):299-302, 305, 309 passim. PubMed ID: 1603758 [TBL] [Abstract][Full Text] [Related]
16. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953 [TBL] [Abstract][Full Text] [Related]
17. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Grossi F; Tiseo M Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211 [TBL] [Abstract][Full Text] [Related]
18. Impact of hematopoietic growth factors on the management of small-cell lung cancer. Demetri GD Chest; 1993 Apr; 103(4 Suppl):427S-432S. PubMed ID: 8384974 [TBL] [Abstract][Full Text] [Related]
19. Haematopoietic growth factors and their therapeutic use. Wadhwa M; Thorpe R Thromb Haemost; 2008 May; 99(5):863-73. PubMed ID: 18449415 [TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Marsh JC; Ganser A; Stadler M Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]